We have recently demonstrated that substitution of imidazoline moieties for the amidine groups of pentamidine produces a molecule that is effective against rat Pneumocystis carinii pneumonia and that is apparently less toxic than pentamidine. For this reason, 10 novel imidazoline substituted compounds were evaluated for their effect against rat P. carinii pneumonia. While was observed with the drug at any of the dose levels or by either of the routes of administration. However, the low solubility of the drug prevented testing at higher i.v. doses. Our conclusion is that DIMP has the potential of providing a safer and more effective alternative to pentamidine for the treatment of P. carinii pneumonia.
Since the 1930s the aromatic diamidine compound pentamidine has been known to be an effective agent for the treatment of parasitic infections (6, 8) . Although it was first discovered to be efficacious against Pneumocystis carinji pneumonia in 1958 (4), numerous side effects limited the use of the drug against P. carinii pneumonia prior to the acquired immunodeficiency syndrome (AIDS) epidemic. Because trimethoprim-sulfamethoxazole, the drug of choice for use in patients with P. carinii pneumonia not associated with AIDS, was found to cause a high frequency of adverse reactions in the treatment of AIDS-related disease (3, 5), a sharp increase was seen in the reliance on pentamidine for P. carinii pneumonia therapy. Recent studies have shown that the toxic side effects can be greatly decreased if the drug is given by aerosol administration (7) . Despite these encouraging developments, there is still an urgent need for an effective and nontoxic alternative drug that can be administered per os or by the parental route for the treatment of P. carinii pneumonia associated with AIDS. Recent observations by ourselves (8a) and others (10) demonstrated that replacement of the amidine groups of pentamidine analogs with imidazoline moieties results in compounds with increased anti-P. carinii pneumonia activity and reduced toxicity. This discovery provided guidance in the search for new anti-P. carinii pneumonia agents.
In the work described here, our on-going screening studies for new therapeutic compounds against P. carinii pneumonia (8a, 9) have been extended to include a series of 10 novel imidazoline-substituted compounds. These compounds were examined for their ability to reduce the mean histologic lung scores in P. carinii-infected rats when the compounds were administered intravenously (i.v.). Two compounds chosen * Corresponding author.
from this study and a promising new derivative of pentamidine (butamidine) taken from a previous screening study (8a) were examined for their effects against P. carinii pneumonia in dose-response experiments. In addition, two compounds were tested for their therapeutic effects against P. carinii pneumonia when administration of the drug was per os.
MATERIALS AND METHODS Pentamidine analogs. All of the compounds tested in this study were synthesized as the mono-or dihydrochloride salts in our laboratory by previously described methods (2). The purity of each drug was determined by high-performance liquid chromatography, elemental analysis, and proton magnetic resonance. Structures of the imidazoline derivatives are shown in Fig. 1 RESULTS AND DISCUSSION Structure-activity studies. Compound structures, activities against P. carinii pneumonia when administered i.v., and toxicities of the 11 diimidazoline-substituted molecules are given in Table 1 . The activities and toxicities of the test compounds were compared with those of the pentamidineand saline-dosed control groups. In general, variation of the central alkyl bridge of from three through five carbons demonstrated that the compounds with an odd number of carbons in the central link produced lower mean histologic scores in the P. carinii-infected rats. The mean histologic scores produced by daily i.v. injections of the three-and five-carbon-chain-unsubstituted compounds (compounds 1 and 9) were 0.5 and 0.7, respectively, while dosing with the corresponding four-carbon compound (compound 5) gave a score of 1.6. Unfortunately, direct comparisons between activity and chain length variation were not possible in the methoxy-substituted compounds (compounds 3, 7, and 10) or derivatives with imidazoline groups in the 3 position (compounds 2 and 6). This circumstance was the result of the necessity of using reduced screening doses of some of the compounds because of either their high toxicities or low solubilities in saline.
The addition of methoxy groups on the aromatic ring in the position meta to the imidazoline moiety (compounds 3, 7, and 10) gave compounds that appeared to be more active, less soluble, and more toxic than the corresponding unsubstituted analogs. However, statistical comparisons were not possible because of differences in dosing levels. One compound (compound 3) in this series proved to be especially interesting. Compound 3 gave a mean histologic score of 0.9 at a relatively low daily dose of 2.5 mg/kg. Although no toxicity was observed at this dose, toxicity could not be evaluated at higher i.v. doses because of the low solubility of the compound. The result of moving the imidazoline moiety from the position para to the ether bridge to the meta position could only be ascertained with the three-carbonchain analogs (compounds 1 and 2). In this case, the derivative with the imidazoline group in the para position (compound 1) proved to be significantly more active (P = 0.001) than the corresponding meta-substituted compound (compound 2). Substitution of a methoxy group para to the imidazoline moiety (compound 4) appeared to increase the 
activity and toxicity of compound 4 relative to those of the unsubstituted analog (compound 2). Finally, placement of a methyl group on an imidazoline nitrogen (compounds 8 and 11) produced highly toxic compounds that showed no activity at the highest nontoxic dose.
Dose-response of butamidine. A comparison of the doseresponse data of 1,4-di(4-amidinophenoxy)butane (butamidine) and pentamidine is presented in Table 3 . At the highest daily dose level evaluated in the dose-response experiment, 10 mg of butamidine per kg was found to be effective (P < 0.001) when compared with saline controls and significantly more potent (P = 0.002) and less toxic than pentamidine. However, reduction of the daily dose of butamidine to 1 mg/kg resulted in the loss of the drug's anti-P. carinji pneumonia properties. A corresponding reduction of the pentamidine dose resulted in a similar loss in activity. Close examination of the data in Table 3 reveals that the doseresponse curves for pentamidine and butamidine are very similar.
Dose-response studies of DIPP. Table 4 outlines the doseresponse studies with 1,3-di(4-imidazolinophenoxy)propane (DIPP). DIPP was significantly more effective than pentamidine (P = 0.001) in reducing the mean histologic score of P. carinii-infected rats with a daily i.v. dose of 10 mg/kg. As with pentamidine, the anti-P. carinii pneumonia activity of DIPP was greatly reduced and not statistically significantly different from that in saline-treated controls when given at a daily i.v. dose of 1.0 mg/kg. Both DIPP and pentamidine were observed to retain some activity against P. carinji pneumonia in rats when the daily i.v. dose was 5 mg/kg. The drug was found to be inactive against P. carinii pneumonia when given by gavage at 20 mg/kg per day.
Dose-response studies of DIMP. The data from the doseresponse experiments for i.v. administration of 1,3-di(4-imidazolino-2-methoxyphenoxy)propane (DIMP) are given in Table 5 . The data for administration of the drug per os are given in Table 6 . Because of the low solubility of the drug, the highest dose administered by the i.v. route in the dose-response study was 2.5 mg/kg. The mean histologic score achieved by this dose was 0.9. The dose-response study revealed that DIMP was only slightly less active when administered at 1.0 mg/kg per day and that the anti-P. carinji pneumonia effect remained significant (P < 0.001) down to a daily dose of 0.5 mg/kg. Activity against P. carinii pneumonia was not significant when the daily i.v. dosage was reduced to 0.25 mg/kg. In addition to the potent activity seen with i.v. injection, DIMP was found to be highly active when it was administered by gavage at daily doses of 40 and 25 mg/kg (Table 6 ). No drug toxicity was observed at the highest gavage dose. Surprisingly, DIMP was observed to be nearly as active when it was administered per os at 25 mg/kg every other day for 2 weeks (Table 6 ). In summary, our initial screening studies indicated that three compounds, the diamidine, butamidine, and the two diimidazolines, DIPP and DIMP, appear to be more effective and less toxic than pentamidine in the rat model of P. carinji pneumonia. The dose-response studies revealed, however, that the anti-P. carinii pneumonia activity of butamidine and DIPP were greatly reduced when drug dosage was decreased 10-fold. In contrast, DIMP given i.v. daily at 1 mg/kg produced an anti-P. carinii pneumonia effect equivalent to that of pentamidine given at 10 mg/kg per day. Significant activity remained when DIMP was given i.v. at 0.5 mg/kg per day. Furthermore, DIMP was highly effective when it was given orally, even when it was administered on an alternateday dosing schedule. No toxicity was observed at any of the i.v. or oral doses used. Thus, the diimidazoline compound DIMP appears to be safer and more effective than pentamidine in the rat model and warrants further detailed investigations to explore its future as an alternative drug for the treatment of P. carinii pneumonia.
